Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa.
Lemos MP, Astronomo RD, Huang Y, Narpala S, Prabhakaran M, Mann P, Paez CA, Lu Y, Mize GJ, Glantz H, Westerberg K, Colegrove H, Smythe KS, Lin M, Pierce RH, Hutter J, Frank I, Mascola JR, McDermott AB, Bekker LG, McElrath MJ. Lemos MP, et al. Among authors: smythe ks. Nat Commun. 2024 Nov 28;15(1):10332. doi: 10.1038/s41467-024-54580-9. Nat Commun. 2024. PMID: 39609400 Free PMC article. Clinical Trial.
PD-L1+ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy.
Hirayama AV, Wright JH, Smythe KS, Fiorenza S, Shaw AN, Gauthier J, Maloney DG, Naresh KN, Yeung CCS, Turtle CJ. Hirayama AV, et al. Among authors: smythe ks. Hemasphere. 2024 Aug 7;8(8):e142. doi: 10.1002/hem3.142. eCollection 2024 Aug. Hemasphere. 2024. PMID: 39113729 Free PMC article.
Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade.
Daniel SK, Sullivan KM, Dickerson LK, van den Bijgaart RJE, Utria AF, Labadie KP, Kenerson HL, Jiang X, Smythe KS, Campbell JS, Pierce RH, Kim TS, Riehle KJ, Yeung RS, Carter JA, Barry KC, Pillarisetty VG. Daniel SK, et al. Among authors: smythe ks. Sci Rep. 2024 Mar 1;14(1):5109. doi: 10.1038/s41598-024-55593-6. Sci Rep. 2024. PMID: 38429349 Free PMC article.
Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade.
Tabachnick-Cherny S, Pulliam T, Rodriguez HJ, Fan X, Hippe DS, Jones DC, Moshiri AS, Smythe KS, Kulikauskas RM, Zaba LC, Paulson KG, Nghiem P. Tabachnick-Cherny S, et al. Among authors: smythe ks. Clin Cancer Res. 2024 Mar 15;30(6):1189-1199. doi: 10.1158/1078-0432.CCR-23-1957. Clin Cancer Res. 2024. PMID: 37851052 Free PMC article.
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI, Wang Y, Pierce RH, Campbell JS, Yushak M, Milhem M, Ross M, Niland K, Arbeit RD, Parasuraman S, Bickley K, Yeung CC, Aicher LD, Smythe KS, Gan L. Andtbacka RHI, et al. Among authors: smythe ks. Cancer Res Commun. 2022 Aug 31;2(8):904-913. doi: 10.1158/2767-9764.CRC-22-0090. eCollection 2022 Aug. Cancer Res Commun. 2022. PMID: 36923305 Free PMC article. Clinical Trial.
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
Church C, Pulliam T, Longino N, Park SY, Smythe KS, Makarov V, Riaz N, Jing L, Amezquita R, Campbell JS, Gottardo R, Pierce RH, Choi J, Chan TA, Koelle DM, Nghiem P. Church C, et al. Among authors: smythe ks. J Immunother Cancer. 2022 Sep;10(9):e005328. doi: 10.1136/jitc-2022-005328. J Immunother Cancer. 2022. PMID: 36252564 Free PMC article.
An In Vivo Model of Human Macrophages in Metastatic Melanoma.
Voillet V, Berger TR, McKenna KM, Paulson KG, Tan WH, Smythe KS, Hunter DS, Valente WJ, Weaver S, Campbell JS, Kim TS, Byrd DR, Bielas JH, Pierce RH, Chapuis AG, Gottardo R, Rongvaux A. Voillet V, et al. Among authors: smythe ks. J Immunol. 2022 Aug 1;209(3):606-620. doi: 10.4049/jimmunol.2101109. Epub 2022 Jul 11. J Immunol. 2022. PMID: 35817516 Free PMC article.
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Wagner MJ, Zhang Y, Cranmer LD, Loggers ET, Black G, McDonnell S, Maxwell S, Johnson R, Moore R, Hermida de Viveiros P, Aicher L, Smythe KS, He Q, Jones RL, Pollack SM. Wagner MJ, et al. Among authors: smythe ks. Clin Cancer Res. 2022 Jun 1;28(11):2306-2312. doi: 10.1158/1078-0432.CCR-22-0240. Clin Cancer Res. 2022. PMID: 35349638 Free PMC article. Clinical Trial.
20 results